• Solitary (sporadic) neurofibromas are common benign soft-tissue tumours; they are among the most frequently encountered peripheral nerve sheath tumours.
• Occur in adults — typically presenting in the 20–40 age range ^[1].
• No significant sex predilection for sporadic solitary neurofibromas.
• When multiple neurofibromas occur, one must consider the phakomatoses (neurocutaneous syndromes), especially Neurofibromatosis Type 1 (NF1) — the most common association ^[2].

Phaeochromocytoma connection: NF1 is associated with a 2–3% risk of phaeochromocytoma ^[3]. This is examined in the endocrine context — NF1 is one of the familial syndromes (alongside MEN2, VHL) that warrant phaeochromocytoma screening.

Peripheral Nerve
├── Epineurium (outermost connective tissue sheath)
│   └── Contains blood vessels (vasa nervorum)
├── Perineurium (surrounds each fascicle)
│   └── Composed of perineurial cells — a blood-nerve barrier
└── Endoneurium (surrounds individual nerve fibres)
    └── Contains Schwann cells, fibroblasts, collagen
        └── Schwann cells myelinate axons (one Schwann cell per internode in myelinated fibres)

A neurofibroma arises from elements within the endoneurium and perineurium:

• Schwann cells — the myelinating/supporting cells
• Perineurial cells — form the perineurial sheath (blood-nerve barrier)
• Fibroblasts — connective tissue cells within the nerve
• Mast cells — resident immune cells (their presence explains the occasional pruritus)

Because the tumour cells are intimately intertwined with the nerve fascicles (unlike schwannomas which push nerve fibres aside), excision of a neurofibroma often requires sacrifice of the parent nerve.

A peripheral nerve runs longitudinally along a limb. Therefore:

• A neurofibroma can be moved in the transverse (lateral) direction but NOT along the longitudinal axis of the nerve ^[1].
• This is a classic examination sign: if you find a subcutaneous lump that moves side-to-side but not up-and-down (along the limb axis), think nerve sheath tumour.

Normal state:

1. Neurofibromin (NF1 gene product) inactivates RAS by converting RAS-GTP (active) → RAS-GDP (inactive).
2. This keeps cell proliferation in check.

In NF1:

1. Loss of neurofibromin → RAS remains constitutively active → downstream activation of RAF → MEK → ERK (MAPK pathway) and PI3K → AKT → mTOR pathway.
2. This drives proliferation of Schwann cells and other nerve sheath progenitors.
3. The tumour microenvironment is enriched with mast cells (recruited by stem cell factor / SCF from Schwann cells), which release growth factors and histamine → explains pruritus and tumour progression.

Two-hit hypothesis applies:

• In NF1 patients: one allele is already mutated (germline). Loss of the second allele (somatic "second hit") in a nerve sheath cell → complete loss of neurofibromin → neurofibroma formation.
• In sporadic neurofibromas: both hits are somatic, occurring in the same cell.

• Unencapsulated (unlike schwannomas)
• Composed of a myxoid matrix with:
  • Wavy, spindle-shaped Schwann cells
  • Fibroblasts
  • Perineurial-like cells
  • Scattered mast cells (highlighted by toluidine blue staining)
  • Residual axons running through the tumour (entrapped)
• Collagen fibres ("shredded carrot" appearance on H&E)
• S-100 positive (Schwann cell marker) but less uniformly than schwannomas

Exam tip: The differential diagnosis specifically listed for neurofibroma is dermal naevus and skin tag ^[2]. These are the most commonly confused lesions clinically.

When a neurofibroma presents in the neck (from cervical nerve roots/plexus), the differential broadens to the general neck mass differential:

These are less commonly tested but important to know exist ^[8]:

There are no formal "diagnostic criteria" for a solitary neurofibroma per se — it is a clinical-pathological diagnosis:

Indications for biopsy/excision ^[1]:

• Diagnosis is in question (atypical features)
• Suspicion of malignancy (rapid growth, pain, change in consistency — red flags for MPNST)
• Patient desires removal for discomfort or cosmetic reasons

This is the high-yield, heavily examined section. When you encounter multiple neurofibromas or café-au-lait macules, you need to apply the NF1 diagnostic criteria.

Updated 2021 International Criteria Note: The revised criteria (Legius et al., Genetics in Medicine 2021) added choroidal abnormalities (detected by OCT or NIR) and a heterozygous pathogenic NF1 variant as additional criteria. A child with one NF1 criterion + a confirmed pathogenic NF1 variant now meets diagnosis. However, the classic CAFESPOT framework is what HKUMed exams test ^[5][6].

Once NF1 is diagnosed (or suspected), a comprehensive investigation panel is required for surveillance of complications. Think of it as screening each organ system that NF1 can affect:

This is the most urgent diagnostic pathway. Red flags: constant significant pain, change in consistency, markedly increased growth ^[5] in a pre-existing neurofibroma.

Nerve conduction studies (NCS) and EMG are relevant when a neurofibroma causes nerve compression or when there is diffuse peripheral neuropathy in NF1:

NCS is ordered when you suspect neuropathy — it measures conduction speed and amplitude of nerve impulse ^[11]. EMG differentiates weakness due to myopathy vs neuropathy/anterior horn cell disease ^[11]. You are not expected to know how to interpret these investigations, but only know when to order one ^[11].

Treatment is usually not necessary for solitary neurofibroma ^[1].

Why? Because:

• The tumour is benign with extremely low malignant potential (solitary cutaneous neurofibromas have virtually zero risk of MPNST)
• It causes no symptoms in most cases — cause no discomfort and not big enough to be disfiguring ^[1]
• Surgery carries the risk of nerve damage (since neurofibroma is intertwined with nerve fibres, unlike schwannoma)

The approach is therefore conservative: reassure the patient, explain the benign nature, and advise to return if the lesion changes.

Surgical excision can be used to remove lesions when diagnosis is in question or when removal is desired due to discomfort or cosmetic reasons ^[1].

Neurofibromas are indicated for removal only when pain, bleeding, interference with function or disfigurement ^[5].

Surgical considerations:

• Nerve sacrifice is often required because tumour cells are intertwined with nerve fascicles (unlike schwannoma where the tumour can be "shelled out")
• For neurofibromas on minor sensory nerves: excision is straightforward
• For neurofibromas on major nerve trunks (e.g., median, ulnar): careful microsurgical dissection with intraoperative nerve monitoring; may need nerve grafting if fascicles must be sacrificed
• Recurrence is possible but uncommon after complete excision of a solitary lesion

This is the backbone of NF1 management. The rationale is that NF1 is a multisystem disorder with age-dependent complications — many of which can be detected early by systematic screening.

NF1 Surveillance ^[5][6]:

Genetic counselling is a cornerstone of NF1 management ^[5][7]:

Complications: Nerve compression ^[2][13]

Why does this happen?

• A neurofibroma grows within or adjacent to a nerve trunk. As it enlarges, it physically compresses the nerve fascicles that run through or alongside it.
• Unlike a schwannoma (which pushes nerve fibres aside eccentrically), a neurofibroma infiltrates between fascicles — so even modest growth can compromise nerve function.

Clinical consequences depend on the nerve involved:

Tinel's sign (pain and paraesthesia on tapping over the lesion) is the clinical manifestation of nerve irritation by the tumour — it represents mechanical stimulation of regenerating or compressed axons ^[1].

Complications: Sarcomatous change — especially in plexiform neurofibroma and NF1 ^[2][13]

This is the most feared complication and the primary reason NF1 patients require lifelong surveillance.

What happens at the molecular level?

1. The neurofibroma already has biallelic NF1 loss (loss of neurofibromin → constitutive RAS activation)
2. Additional "hits" accumulate over time in tumour suppressor genes:
   • TP53 loss (guardian of the genome — normally triggers apoptosis in damaged cells)
   • CDKN2A/p16 loss (normally restrains cell cycle at G1/S checkpoint)
   • SUZ12/EED loss (polycomb repressive complex 2 — epigenetic regulation)
3. These combined losses → malignant peripheral nerve sheath tumour (MPNST)

Key facts about MPNST:

Cerebrovascular dysplasia (2–6%) ^[5][6]:

Neurologic disorders that may require specific management include cognitive deficits, learning disabilities, seizures, and peripheral neuropathy ^[7].

These are under-recognised but profoundly affect quality of life: